HIV 1/2 Antigen/Antibody Pretransplant only

Sunquest Code:HIGBNC  
Epic Code:LAB6466Epic Name:HIV Antigen Antibody Combo Pretransplant
Synonyms:Human Immunodeficiency Virus Antigen/Antibody Combination
Methodology:Chemiluminescent immunoassay
Turnaround Time:Performed Mon-Fri; results are reported within 3 days.
Special Instructions:It is recommended that HIV testing be discussed with the patient prior to collection of the specimen. Written patient consent for HIV testing is not required.
Associated Links:

HIV Diagnostic Algorithm

Collection Instructions

Optimal Volume:3 mL
Minimum\Peds Volume:2.2 mL
Container:Red or gold (gel) (Green (lithium heparin, no gel), Green (lithium heparin, gel), Purple (EDTA), Red (no gel))
Causes for Rejection:Grossly hemolyzed, heat-inactivated or microbial contamination.

Processing and Shipping

Specimen Processing:Centrifuge and leave sample in serum separator tube (preferred). If necessary, aliquot 1.5 mL, 1 mL minimum. Store in refrigerator up to 7 days.
Shipping Instructions:Ship at refrigerated temperature.
Test Performed at or Referral Lab Specialty Core  (UMMC-East Bank)


Reference Range:
New HIV Diagnostic Testing Algorithm Effective July 20, 2016, Fairview Laboratories will be replacing the Multispot Differentiation test, which is no longer manufactured, with the FDA approved Geenius™ HIV 1 / 2 Supplemental Assay.   The testing algorithm begins with the Abbott HIV-1/2 AG/AB screening immunoassay that simultaneously detects both antibody to human immunodeficiency virus (HIV) and HIV p24 antigen on the Abbott Architect instrument, performed at the East Bank campus. If the patient specimen is repeatedly reactive with the screening assay, it will be tested using the HIV Geenius (BioRad) HIV-1/2 immunoassay, which can differentiate between HIV-1 and HIV-2 antibodies. If the differentiation assay is also reactive, the presence of HIV-1 or HIV-2 antibodies is established. Specimens non-reactive with the HIV Geenius are reported as indeterminate and further testing with a qualitative or quantitative nucleic acid amplification test (NAT) should be performed to identify or rule out acute HIV-1 infection. If both HIV-1 and HIV-2 are positive, additional testing is required to rule out dual infection. The new HIV-1/2 algorithm enhances early detection of HIV infection by shortening the "window period" in which infection cannot be detected. Plasma and serum are acceptable for this assay. This assay will replace the current HIV antibody assay.  

Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact: for TestID: 6281"